Document is current
Any future updates will be listed below
-
Authors
Suarez-Carmona, Meggy
Hampel, Mareike
Zhang, Xin-Wen
Pöchmann, Alexandra
Grauling-Halama, Silke A.
Valous, Nektarios A.
Charoentong, Pornpimol
Ferber, Dyke
Wissfeld, Jannis
Höflich, Alicia
Goriely, Stanislas
Detavernier, Aurélie
Azouz, Abdulkader
Rongvaux, Anthony
Zukunft, Sven https://orcid.org/0000-0002-1811-4562
Fleming, Ingrid https://orcid.org/0000-0003-1881-3635
Okun, Jürgen G.
Baracos, Vickie
Heikenwalder, Mathias
Zitvogel, Laurence https://orcid.org/0000-0003-1596-0998
Xu, Xinyi
Xu, Chenqi https://orcid.org/0000-0002-4968-6782
Volkmar, Michael
Schraivogel, Daniel https://orcid.org/0000-0002-5734-6980
Steinmetz, Lars
Hamanishi, Junzo
Mandai, Masaki
Gaida, Matthias
Mokry, Theresa
Nattenmüller, Johanna
Sedlaczek, Oliver
Monje, Nanna
Schwab, Roxana
Hasenburg, Annette
Mavratzas, Athanasios
Boger, Regina Johanna
Marmé, Frederik https://orcid.org/0000-0002-6591-3367
Schott, Sarah
Halama, Niels
-
Funding
Funding for this research was provided by:
Helmholtz Association (Zukunftsthema)
Wallonie-Bruxelles International
Fonds De La Recherche Scientifique - FNRS
Fédération Wallonie-Bruxelles (ERDF 2022-2027 WAL IMAGIN SYST-IMM)
Stichting Tegen Kanker
Deutsche Forschungsgemeinschaft (318346496)
- License Information
-
More Information
Article History
Received: 3 April 2025
Revised: 12 December 2025
Accepted: 13 January 2026
First Online: 4 March 2026
Competing interests
: University of Heidelberg, Germany, and N.H. have intellectual property for the use of CCR5 inhibition in other solid cancers. All the other authors declare that they have no competing interests. The authors declare that they have no competing interests.
